Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

Abstract Number: 1592 • ACR Convergence 2024
Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes
Federica Pallotti¹, Camille Mettler², Roberto Padoan³, Francesca Regola⁴, Franco Franceschini⁵, Sergey Moiseev⁶, Pavel Novikov⁷, Mario Andrea Piga⁸, Gianluca Moroncini⁹, Silke Brix¹⁰, Abdul Hadi Kafagi¹¹, Samuel Deshayes¹², Achille Aouba¹², Julien Campagne¹³, Paolo Delvino¹⁴, Jan Willem Cohen Tervaert¹⁵, Luisa Brussino¹⁶, Martin Michaud¹⁷, Nils Venhoff¹⁸, Federico Alberici¹⁹, Claudia Iannone²⁰, Sophie Rosenstingl²¹, Marin Moutel²², Jean-Marc Galempoix²³, Vincent Cottin²⁴, Clara Jaccard²⁵, Diane Riehl²⁶, Paul Legendre²⁷, Anne-Claire Billet²⁸, Paola Parronchi²⁹, Luca Quartuccio³⁰, Vítor Silvestre Teixeira³¹, Allyson Egan³², David Jayne³², Enrico Tombetti³³, Marco Caminati³⁴, Christian Pagnoux³⁵, Alexis Régent³⁶, Marc Ruivard³⁷, Loïc Guillevin³⁸, Xavier Puéchal³⁶ and Benjamin Terrier³⁹, and the French Vasculities Study Group and European EGPA Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ⁴Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, ⁵Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁶Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia, ⁷Sechenov First Moscow State Medical University, Moscow, Russia, ⁸Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, ⁹Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, ¹⁰Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, ¹¹Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, ¹²Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ¹³Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹⁴University of Milano-Bicocca, Milan, Milan, Italy, ¹⁵University of Alberta, Edmonton, Canada, ¹⁶SSDDU Immunologia Clinica ed Allergologia, AO Mauriziano, Turin, Italy, ¹⁷Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, ¹⁸Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, ¹⁹Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, ²⁰Department of Rheumatology, University of Milan, and Rheumatology Department, ASST Pini-CTO, Milan, Italy, ²¹Service Médecine Interne, Centre hospitalier intercommunal Compiègne Noyon, Compiègne Noyon, France, ²²Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospital, Reims, France, ²³J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières, France, ²⁴Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Lyon, France, ²⁵Gaston Bourret Hospital, Nouméa, New Caledonia, ²⁶Centre hospitalier intercommunal Toulon- La Seyne Sur Mer, Toulon, France, ²⁷Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ²⁸Department of Internal Medicine, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, ²⁹University of Florence, Florence, Florence, Italy, ³⁰Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³¹Department of Rheumatology, Faro Hospital, Algarve, Portugal, ³²University of Cambridge, Cambridge, United Kingdom, ³³Internal Medicine and Rheumatology, Department of Biomedical and Clinical Sciences, Sacco and Fatebenefratelli Hospitals, Milan, Italy, Milan, Italy, ³⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ³⁵Mount Sinai Hospital, Toronto, ON, Canada, ³⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ³⁷Internal Medicine Department, Estaing University Hospital, CHU Clermont-Ferrand, Clermonnt-Ferrand, Italy, ³⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ³⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Although these entities are often easily distinguished in…
Abstract Number: 2491 • ACR Convergence 2024
Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, Danuta Kielar⁵, Juliana Meyers⁶, Elizabeth Esterberg⁶, Tram Nham⁶ and Stephanie Y. Chen⁷, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, ⁶RTI Health Solutions, Research Triangle Park, NC, ⁷BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
Abstract Number: 1593 • ACR Convergence 2024
Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis
Federica Pallotti¹, Philippe Bonniaud², Perrine SMETS³, stephanie Habib⁴, Amandine Perier⁵, Alban Deroux⁶, Julie Mankikian⁷, Antoine Neel⁸, Clémentine Rousselin⁹, Raphaele Seror¹⁰, Camille Taille¹¹, Etienne Crickx¹², Candice La Croix¹³, Philippe Blanche¹⁴, Loïc Guillevin¹⁵, Xavier Puéchal¹⁶ and Benjamin Terrier¹⁷, and French Vasculitis Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ³Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁴Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁵CH de Niort, Niort, France, ⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁷CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, ⁸Department of Internal Medicine, CHU Nantes, Nantes, France, ⁹Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹¹Bichat Hospital, Paris, France, ¹²Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, ¹³Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, ¹⁴Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, ¹⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
Abstract Number: 2691 • ACR Convergence 2024
Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Roberto Ríos-Garcés¹, Núria Farran¹, Salvador Naranjo-Suarez², Roser Alba-Rovira¹, Sergio Prieto-González³, Itziar Tavera-Bahillo¹, Roser Solans-Laqué⁴, Ebymar Arismendi⁵, Marc Corbera-Bellalta¹, Javi Marco-Hernández¹, Farah Kamberovic¹, Nina Visocnik¹, Maria Cid⁶ and Georgina Espígol-Frigolé¹, ¹Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, ⁴Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ⁵Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, ⁶Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain
Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
Abstract Number: 1594 • ACR Convergence 2024
Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification
Michele Moretti¹, Francesco Ferro², Irene Martelli³, Francesca Pistone³, Giulia Greco³, Federica Di Cianni⁴, Nazzareno Italiano⁵, ROSARIA TALARICO⁴, Veronica Seccia⁶, Chiara Baldini⁷, Ilaria Puxeddu³ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴University of Pisa, Pisa, Italy, ⁵University of Pisa, Rovigo, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
Abstract Number: 1596 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Bernhard Hellmich¹, Peter Merkel², David Jayne³, Benjamin Terrier⁴, Florence Roufosse⁵, Parameswaran Nair⁶, Nader Khalidi⁶, David J. Jackson⁷, Shunsuke Furuta⁸, Lena Börjesson Sjö⁹, Sofia Necander⁹, Anat Shavit¹⁰, Claire Walton¹¹ and Michael Wechsler¹², ¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²University of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁶McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁷Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, ⁸Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹¹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹²National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
Abstract Number: L14 • ACR Convergence 2023
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
Michael Wechsler¹, Parameswaran Nair², Benjamin Terrier³, Bastian Walz⁴, Arnaud Bourdin⁵, David Jayne⁶, David Jackson⁷, Florence Roufosse⁸, Lena Börjesson Sjö⁹, Ying Fan¹⁰, Maria Jison¹⁰, Christopher McCrae¹¹, Sofia Necander⁹, Anat Shavit¹², Claire Walton¹² and Peter Merkel¹³, ¹National Jewish Health, Denver, CO, ²McMaster University, Hamilton, ON, Canada, ³Cochin Hospital, Paris, France, ⁴University of Tübingen, Kirchheim-Teck, Germany, ⁵University of Montpellier, CHU Montpellier, INSERM, Montpellier, Montpellier, France, ⁶Addenbrooke's Hospital, Cambridge, United Kingdom, ⁷Guy's Severe Asthma Centre, School of Immunology & Microbial Sciences, King's College London,, London, United Kingdom, ⁸Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gaithersburg, MD, ¹¹Translational Science & Experimental Medicine, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹²BioPharmaceutials Medical, AstraZeneca, Cambridge, United Kingdom, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Eosinophilic inflammation is a key pathophysiological mechanism of eosinophilic granulomatosis with polyangiitis (EGPA). Oral glucocorticoids (OGCs) and immunosuppressants remain the basis for the standard…
Abstract Number: 0854 • ACR Convergence 2023
Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Martin Dutertre¹, Gregory Pugnet², Claire De Moreuil³, Bernard Bonnotte⁴, YGAL BENHAMOU⁵, Dominique Chauveau⁶, Elisabeth Diot⁷, Pierre Duffau⁸, Nicolas Limal⁹, Antoine Néel¹⁰, GEOFFREY URBANSKI¹¹, Noémie Jourde-Chiche¹², Nicolas MARTIN SILVA¹³, Francois Maurier¹⁴, Arsène Mekinian¹⁵, Nicolas Schleinitz¹⁶, Felix ackermann¹⁷, Anne-Laure Fauchais¹⁸, Antoine Froissart¹⁹, Thomas Le Gallou²⁰, Yurdagul Uzunhan²¹, Jean-Francois Viallard²², Alice Berezne²³, laurent chiche²⁴, Bruno Crestani²⁵, Guillaume Direz²⁶, Cecile-Audrey DUREL²⁷, Pascal Godmer²⁸, Jean-Emmanuel Kahn²⁹, Marc Lambert³⁰, Mathilde de Menthon¹, Thomas Quemeneur³¹, Jacques Cadranel¹, Pierre Charles³², Antoine Dossier¹, Loic Guillevin³³, Xavier Puéchal³⁴ and Benjamin Terrier³⁵, ¹AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³CHU de Brest, Brest, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁵rouen university hospital, Rouen, France, ⁶Hôpital Le Tripode, Bordeaux, France, ⁷Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹AP-HP, Créteil, France, ¹⁰CHU de Nantes, Nantes, France, ¹¹CHU Angers, Angers, France, ¹²AP-HM, Marseille, France, ¹³CHU Caen, Caen, France, ¹⁴Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁵Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁶Aix Marseille university, AP-HM, Marseille, France, ¹⁷Hôpital Foch, Suresnes, France, ¹⁸Dupuytren Hospital, Limoges, France, ¹⁹CHI Créteil, Créteil, France, ²⁰CHU Rennes, Rennes, France, ²¹AP-HP, Bobigny, France, ²²CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²³CH Annecy, Annecy, France, ²⁴Hopital Europeen, Marseille, France, ²⁵Hopital Bichat, Paris University, Paris, France, ²⁶CH Le Mans, Le Mans, France, ²⁷Hospices Civils de Lyon, Lyon, France, ²⁸CH Bretagne Atlantique, Vannes, France, ²⁹AP-HP, Suresnes Cedex, France, ³⁰CHRU Lille, Lille, France, ³¹CH Valenciennes, Valenciennes, France, ³²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ³³University Paris Descartes, Paris, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
Abstract Number: 0856 • ACR Convergence 2023
Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Berengere Molina¹, Roberto Padoan², Maria Letizia Urban³, Pavel Novikov⁴, Marco Caminati⁵, Camille Taillé⁶, Antoine Néel⁷, Laurence Bouillet⁸, Paolo Fraticelli⁹, Nicolas Schleinitz¹⁰, Christine Christides¹¹, Laura Moi¹², Bertrand Godeau¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Vincent Cottin¹⁸, Cécile-Audrey Durel¹⁹, Elena Gelain²⁰, Boris Lerais²¹, Marc Ruivard²², Matthieu Groh²³, Maxime Samson²⁴, Luca Moroni²⁵, Jens Thiel²⁶, Anna Kernder²⁷, Jan Willem Cohen Tervaert²⁸, Giulia Costanzo²⁹, Marco Folci³⁰, Sonia Rizzello³¹, Pascal Cohen³², Giacomo Emmi³³ and Benjamin Terrier³⁴, ¹Cochin Hospital, Paris, France, ²Department of Medicine DIMED, University of Padova, Padova, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Sechenov First Moscow State Medical University, Moscow, Russia, ⁵University of Verona, Verona, Italy, ⁶AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ⁷CHU Nantes, Nantes, France, ⁸Internal medicine department, Grenoble University Hospital, Grenoble, France, ⁹University Hospital Ospedali Riuniti, Ancona, Italy, ¹⁰Aix Marseille university, AP-HM, Marseille, France, ¹¹Avignon Hospital, Avignon, France, ¹²Valais Hospital, Sion, Switzerland, ¹³CHU Henri Mondor, Créteil, France, ¹⁴Uppsala University, Uppsala, Sweden, ¹⁵ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ¹⁶CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, ¹⁷CHU Besancon, Besançon, France, ¹⁸Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Meyer Children's Hospital, Florence, Italy, ²¹Brest University Hospital, Brest, France, ²²CHU Clermont Ferrand, Clermont Ferrand, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²⁵San Raffaele Scientific Institute, Milan, Italy, ²⁶University Hospital Freiburg, Freiburg, Germany, ²⁷Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, ²⁸University of Alberta, Edmonton, AB, Canada, ²⁹University of Cagliari, Monserrato, Italy, ³⁰Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy, ³¹Careggi University Hospital, Florence, Italy, ³²CHU Cochin, Paris, France, ³³University of Florence, Florence, Italy, ³⁴Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…
Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Ricardo Blanco¹, Iñigo Rúa-Figueroa², Roser Solans³, Maria C Cid⁴, Marina Blanco⁵, Ismael Garcia Moguel⁶, Francisco Perez Grimaldi⁷, Ana Noblejas⁸, Moises Labrador³, Cristian Domingo⁹, Georgina espigol¹⁰, Fernando Sanchez Toril¹¹, Francisco Ortiz-Sanjuán¹², Ebymar Arismendi¹³ and Jose María Alvaro-Gracias¹⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, ⁶Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, ⁷Pneumology Department, H. University of Jerez, Cádiz, Spain, ⁸Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, ¹¹Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, ¹²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ¹³Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
Abstract Number: 1547 • ACR Convergence 2023
Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing small-to-medium vessel vasculitis with a relapsing-remitting course involving prodromal (various allergic reactions), eosinophilic (infiltration into…
Abstract Number: 1548 • ACR Convergence 2023
Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Raising awareness of eosinophilic granulomatosis with polyangiitis (EGPA), a rare necrotizing small-to-medium vessel vasculitis, amongst clinicians is important to ensure timely diagnosis and treatment.…
Abstract Number: 1549 • ACR Convergence 2023
Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, immune-inflammatory disorder characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation, and chronic necrotizing vasculitis of small-to-medium-sized blood…
Abstract Number: 1552 • ACR Convergence 2023
Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
Benjamin Terrier¹, Camille Taillé², Alice Brouquet³, Solenne Tauty³, Francoise Bugnard³, Loic Guillevin⁴, Xavier Puéchal⁵ and Vincent Cottin⁶, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, ³Steve Consultant, Lyon, France, ⁴University Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
Abstract Number: 1553 • ACR Convergence 2023
Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis
Yeliz Yagiz Ozogul¹, Sinem Nihal Esatoglu², Murat Ozogul³, Osman Kizilkilic⁴, Yesim Ozguler⁵, Ugur Uygunoglu⁶, Vedat Hamuryudan² and Gulen Hatemi², ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey
Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].